Systemic anticoagulation was found to improve quality-adjusted life years among patients with idiopathic pulmonary arterial hypertension but not among those with connective tissue disease-associated pulmonary arterial hypertension.
No causal association between elevated red cell distribution width and pulmonary arterial hypertension was established.
Cardiac magnetic resonance imaging is useful for risk stratification in patients with pulmonary arterial hypertension.
A new consensus survey of expert opinions was published regarding the use of oral prostacyclin pathway agents in patients with various forms of pulmonary arterial hypertension.
In patients with pulmonary arterial hypertension, cardiac magnetic resonance imaging metrics are capable of identifying individuals at a low risk for 1-year mortality.
This study assessed improvement in pulmonary vascular resistance and cardiac index in patients with pulmonary arterial hypertension who rapidly inhale iloprost 2.5 ug via the Breelib™ nebulizer.
A high probability of pulmonary hypertension as assessed with echocardiography was found to be a better predictor of mortality and readmission than left ventricular ejection fraction and right ventricular function in patients with acute decompensated heart failure.
Emerging evidence suggests that the extrapulmonary effects of pulmonary arterial hypertension may manifest in the form of vascular dysfunction in systemic circulation, metabolic/endocrine dysfunction, and skeletal and respiratory muscle dysfunction.
Clinical experts in pulmonary arterial hypertension (PAH) identified certain hemodynamic variables as predictive of patient survival that were different from variables found in major clinical trials.
Combination therapy consisting of once-daily macitentan and tadalafil was associated with reductions in pulmonary vascular resistance in patients with pulmonary arterial hypertension.
